Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Malcolm Spicer

Senior Editor, Consumer Health

Washington, DC
Malcolm Spicer is lead analyst for Pharma intelligence | informa's coverage of the consumer health care products industries. He provides comprehensive and insightful reporting on manufacturing, marketing, regulation, legislation, financial and research news about the nonprescription drug and nutritional product industries. He has worked in this post for 10 years and previously reported for other publications on regulation of the health care industry, on the telecommunications and internet technologies and on the US energy market.
Advertisement
Set Alert for Articles By Malcolm Spicer

Latest From Malcolm Spicer

Consumer Business Reliable And Right At Home At GlaxoSmithKline

CEO Walmsley's familiarity with Glaxo's consumer health business was clear in her response to analysts' questions about the firm's future as a three-unit operation. The business marketing brands including Flonase and Excedrin is a more reliable revenue driver than the pharma business, she said.

Consumer Consumer

Hatch Question, Gottlieb Response Speak Volumes About DSHEA Reliance

Gottlieb is not the first FDA commissioner nominee to profess support for its regulatory framework established by DSHEA, but the focus of Hatch's question serves stronger notice than similar questions asked of previous candidates that the agency authority to enforce in the space does need adjustment.

United States Dietary Supplements

Cancer Claim Warnings Show FDA Resolve Against Mounting Online Odds

FDA realizes more products labeled as supplements but making claims to treat cancer or other serious conditions are available online from firms that have not been identified in ongoing searches by "staff devoted to rooting out health fraud scams."

United States Dietary Supplements

HGH Import Alert Grows From 4 Products To 32 In 8 Months

An April 18 alert update about a Chinese firm distributing HGH-containing supplements follows the launch of the alert in September and an update in November about other firms in the country reported as shipping supplements tainted with the ingredient.

China Asia Pacific

FDA Supplement GMP Recordkeeping Estimate Fails Industry Proofread

Like FDA's draft guidance on NDI notifications and its previous estimates for compliance with that regulation and the GMP final rule, the agency's latest estimate on manufacturers' annual burdens associated with GMP recordkeeping prompts industry questions.

United States Dietary Supplements

FTC Could Open Arms For Health Claim Science In Regulatory Review

FTC is implementing Trump administration directives on "eliminating wasteful, unnecessary regulations and processes," but attempting to reduce regulated industries' compliance burden is not the same as slowing FTC enforcement against false and misleading advertising, attorneys say.

United States Dietary Supplements
See All
Advertisement
UsernamePublicRestriction

Register